Restart Life Sciences Reports Second Quarter 2026 Results Highlighted by 146% Sequential Revenue Growth
Restart Life Sciences posts first-half revenue of $465,715 and expands Holy Crap’s retail and online footprint while maintaining over 39% gross margins.
Rhea-AI Summary
Restart Life Sciences (NMLSF) reported Q2 2026 results showing 146% sequential revenue growth as it transitions into a revenue-producing consumer packaged goods business following the Holy Crap Foods acquisition.
Total revenue for H1 2026 was $465,715, compared with nil in H1 2025. Q2 2026 revenue reached $331,162, with Holy Crap generating about $110,000 in June alone at approximately 35% gross margins, a 64.2% year-over-year increase for the brand. Q2 gross profit was $130,699, a 39.5% gross margin, and H1 gross profit was $192,636, a 41.4% gross margin.
Total assets were $1,903,647 as of June 30, 2026, up from $1,767,208 at year-end 2025, with shareholders' equity at $1,324,748. Operational initiatives included a Walmart.ca listing, entry into the U.S. via Amazon, a Caribbean pilot, launch of a new protein-focused product line, and continued evaluation of M&A opportunities.
Positive
- H1 2026 revenue $465,715 versus nil in H1 2025, reflecting initial commercialization
- Q2 2026 revenue $331,162, a 146% sequential increase over Q1 2026
- Holy Crap June 2026 revenue ~$110,000 with ~35% gross margin, up 64.2% year over year
- Q2 2026 gross profit $130,699 with 39.5% gross margin; H1 gross margin 41.4%
- Total assets $1,903,647 at June 30, 2026, up from $1,767,208 at December 31, 2025
- New distribution and market access via Walmart.ca, Amazon USA, and a Caribbean pilot
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Vancouver, British Columbia--(Newsfile Corp. - September 3, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce its financial and operating results for the three and six months ended June 30, 2026. All financial figures are expressed in Canadian dollars ($) unless otherwise noted, are prepared in accordance with International Financial Reporting Standards (IFRS), and are unaudited.
In the second quarter of 2026, Restart Life Sciences continued its operational transition following the acquisition of
Q2 2026 & H1 2026 Financial Highlights
- Initial Revenue Generation: Total revenue for the six months ended June 30, 2026 (H1 2026) was
$465,715 , compared to $Nil in the prior-year period (H1 2025). - Quarter-over-Quarter Revenue: Revenue for the three months ended June 30, 2026 (Q2 2026) was
$331,162 . This represents a146% sequential increase over Q1 2026, reflecting the ongoing integration of Holy Crap's operations. - Brand Performance: Holy Crap generated approximately
$110,000 in revenue in June 2026 with apx35% gross margins. This represents a64.2% year-over-year increase for the brand, supported by sales across its wholesale, distribution, and e-commerce channels. - Gross Margins: Q2 2026 Gross Profit was
$130,699 , representing a39.5% gross margin. For the first half of the year, Gross Profit was$192,636 , achieving an overall41.4% gross margin. - Balance Sheet Updates: The Company's total asset base was
$1,903,647 as at June 30, 2026 (up from$1,767,208 at December 31, 2025). Shareholders' Equity was$1,324,748 .
"Our management team remains focused on strategic growth, revenue generation, and market expansion," stated Steve Loutskou, CEO of Restart Life. "Transitioning from a non-revenue issuer a year ago to reporting
During the period and subsequent to the quarter end, the Company advanced several operational initiatives:
- Walmart Canada Listing: On April 28, 2026, the Company announced that Holy Crap secured a listing on Walmart Canada's online marketplace, Walmart.ca. The initial product lineup has been accepted, exposing the brand to new Canadian consumers.
- U.S. and International Pilot: On May 13, 2026, the Company announced its entry into the U.S. market through Amazon USA. Furthermore, on June 10, 2026, the Company launched a multi-month market pilot in the Caribbean via a local on-demand delivery platform to evaluate international demand.
- Product Development: As previously announced on March 3, 2026 and April 30, 2026, following a collaboration with the University of Manitoba's Richardson Centre for Food Technology and Research (RCFTR), the Company has commenced commercial production of a new protein-focused product line. The Company also continues to develop specific formulations targeting youth and senior consumer segments.
- Digital Integration: The Company is integrating AI-driven tools and customer relationship management platforms to support online sales, customer engagement, and operational efficiency.
- M&A Evaluation: Utilizing its operational manufacturing facility, management continues to evaluate targeted merger and acquisition opportunities within the health and CPG sectors. The Company is focused on established, revenue-generating businesses that align with its existing infrastructure. While the goal of these evaluations is to support future revenue growth, any potential acquisitions are subject to capital availability, integration risks, and standard closing conditions. There can be no assurance that these efforts will result in completed transactions or anticipated financial growth.
Restart Life Sciences would like to thank its shareholders for their ongoing support as the Company advances its mission and continues to
About Restart Life Sciences Corp.
Restart Life Sciences Corp. is a Canadian-based life sciences company listed on the CSE. For more information about Restart Life, please visit the Company's website at www.restartlife.co.
About Holy Crap Foods Inc.
Holy Crap Superseed Cereal and Holy Crap Superseed Oatmeal are premium functional food brands offering nutrient-dense, clean-label products made with simple, high-quality ingredients. Based in Gibsons, British Columbia, the brand has built a loyal and growing customer base across Canada, driven by strong consumer trust and repeat purchases.
Positioned within the fast-growing gut health and wellness category, Holy Crap's gluten-free, non-GMO, high-fiber products support digestive health and sustained energy, while gaining traction as a trusted, everyday solution for health-conscious consumers. For more information, visit www.holycrap.com
Forward-Looking Statements
This news release contains statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Restart Life Sciences' actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
On behalf of the Board of Directors
Steve Loutskou
Chief Executive Officer, Restart Life Sciences Corp.
Tel: +1 (778) 819-0244
Email: hello@restartlife.co
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/312691